PMID- 31257438
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20210110
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Jan 1
TI  - Antiphospholipid antibody levels in early systemic lupus erythematosus: are they 
      associated with subsequent mortality and vascular events?
PG  - 146-152
LID - 10.1093/rheumatology/kez239 [doi]
AB  - OBJECTIVES: aPL are present in between 20 and 30% of patients with SLE. They can 
      cause vascular events (VE) or pregnancy morbidity. aCL and 
      anti-beta-2-glycoprotein I (anti-beta2GPI) are measured in clinical practice. Domain 
      I (DI) of beta2GPI is the main site for aPL binding. We investigated the prevalence 
      of IgG anti-DI, aCL and anti-beta2GPI antibodies in early SLE and their association 
      with mortality and development of VE. METHODS: Samples from 501 patients with SLE 
      that had been obtained and stored early during their disease were tested for IgG 
      anti-DI, aCL and anti-beta2GPI antibodies by ELISA. LA status and history of VE were 
      obtained by reviewing medical records. Kaplan-Meier analysis was used to 
      investigate mortality and occurrence of VE, comparing groups with and without aPL 
      in early disease. RESULTS: Of 501 patients, 190 (38%) had at least one of these 
      aPL, of whom 112 had anti-DI alone. Of 276 patients with complete vascular 
      history, 83 had experienced VE. The 39 patients who were double or 
      triple-ELISA-positive for any combination of the three aPL were more likely to 
      have or develop lupus anticoagulant (P<0.0001) than those who were 
      single-ELISA-positive or negative. In Kaplan-Meier analysis, they showed a trend 
      towards developing more VE (P = 0.06). CONCLUSION: IgG anti-DI antibodies were 
      present in early serum samples from 29% of patients and were more common than IgG 
      aCL or anti-beta2GPI. There was some evidence suggesting that double or 
      triple-ELISA-positivity for these antibodies identified a group with worse 
      outcomes.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Pericleous, Charis
AU  - Pericleous C
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - D'Souza, Amrita
AU  - D'Souza A
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - McDonnell, Thomas
AU  - McDonnell T
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - Ripoll, Vera M
AU  - Ripoll VM
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - Leach, Oliver
AU  - Leach O
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - Isenberg, David
AU  - Isenberg D
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - Giles, Ian
AU  - Giles I
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
FAU - Rahman, Anisur
AU  - Rahman A
AD  - Division of Medicine, Centre for Rheumatology Research, University College 
      London, London, UK.
LA  - eng
GR  - 19423/VAC_/Versus Arthritis/United Kingdom
GR  - MR/P017371/1/MRC_/Medical Research Council/United Kingdom
GR  - 21223/VAC_/Versus Arthritis/United Kingdom
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Immunoglobulin G)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Anticardiolipin/blood
MH  - Antibodies, Antiphospholipid/*blood
MH  - Cardiovascular Diseases/*immunology/*mortality
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Infant
MH  - Lupus Erythematosus, Systemic/blood/*immunology/*mortality
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Young Adult
MH  - beta 2-Glycoprotein I/immunology
PMC - PMC6909892
OTO - NOTNLM
OT  - anti-DI
OT  - anti-phospholipid antibodies
OT  - anti-phospholipid syndrome
OT  - beta-2-glycoprotein I
OT  - mortality
OT  - systemic lupus erythematosus
OT  - vascular thrombosis
EDAT- 2019/07/02 06:00
MHDA- 2020/04/25 06:00
PMCR- 2019/06/30
CRDT- 2019/07/02 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/05/13 00:00 [revised]
PHST- 2019/07/02 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2019/07/02 06:00 [entrez]
PHST- 2019/06/30 00:00 [pmc-release]
AID - 5525320 [pii]
AID - kez239 [pii]
AID - 10.1093/rheumatology/kez239 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2020 Jan 1;59(1):146-152. doi: 
      10.1093/rheumatology/kez239.